Legora Raises $150 Million Series C to Accelerate Global Rollout of Its AI Platform for Legal Professionals
30.10.2025 11:00:00 CET | Business Wire | Press Release
Legora, the collaborative AI platform for lawyers, today announced the completion of a Series C round of $150 million at a $1.8 billion valuation, led by Bessemer Venture Partners, with significant investment from existing investors ICONIQ, General Catalyst, Redpoint Ventures, Benchmark, and Y Combinator, to accelerate its global expansion and growing product roadmap.
The funding round takes place against a backdrop of rapidly increasing demand for Legora’s AI-powered platform for legal professionals over the past six months. Since May 2025, Legora’s customer base has grown from 250 to over 400, while the number of markets served has doubled from 20 to more than 40.
Legora now partners with many of the world’s most prestigious enterprises and law firms – including Linklaters, Cleary Gottlieb, Goodwin, and MinterEllison – not just as customers, but as strategic collaborators. Tens of thousands of legal professionals use Legora every day to review and research with precision, draft smarter, and collaborate seamlessly.
Max Junestrand, CEO and co-founder of Legora, said:
“We are seeing astronomical demand for our product. Legal professionals across the globe are adopting AI into their work at an unprecedented rate, and I could not be more proud of supporting our customers on this journey. I’m grateful for the strong backing of our investors, which enables us to execute on our vision: enabling the lawyer of the future and seamless collaboration between machine and human intelligence.”
Legora’s success is driven by its collaborative approach to developing and embedding AI. More than a platform, Legora is a trusted partner to its clients – working side by side from the very first interaction through full-scale rollout and beyond. This ensures solutions that are seamlessly aligned with client needs and embraced across entire organizations, driving immediate impact and lasting transformation in the legal profession.
“Legora exemplifies how the most transformative AI companies fundamentally reimagine how work gets done – they've built not just another legal tech tool, but a collaborative AI platform that elevates the practice of law itself,” said Sameer Dholakia, partner, Bessemer Venture Partners. “Max and his team's customer-obsessed approach and exceptional product velocity position Legora to lead the AI transformation of the trillion-dollar legal services industry.”
With offices in Stockholm, London, New York, Denver, and Sydney, Legora has built a team of nearly 200 legal experts and technologists. In the year ahead, the company aims to more than double in size and establish additional global hubs, strengthening its ability to meet the needs of an expanding international client base.
Max Junestrand added:
“Legora is quickly becoming the go-to partner for legal professionals worldwide – making their work easier, more rewarding, and more profitable. We’ve made great progress, but we are only getting started, and executing on our vision will demand relentless focus and hard work from the entire team. We're excited for the next stage of our journey and the opportunity to create long-lasting impact across the legal profession.”
About Legora
Legora’s collaborative AI platform helps lawyers review and research faster, draft smarter, and advise with precision. Backed by world-class investors such as Bessemer Venture Partners, ICONIQ, General Catalyst, Redpoint Ventures, Benchmark, and Y Combinator, Legora serves more than 400 leading law firms and in-house legal teams in over 40 markets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251030974157/en/
Contacts
legora@firstlightgroup.io
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom